Diabetes news
-
Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review
7 October 2026 · Frontiers in Endocrinology
A new *Frontiers in Endocrinology* paper reports a rare case of fulminant type 1 diabetes mellitus linked to pembrolizumab, an immune checkpoint inhibitor widely used in cancer treatment. The case involved a young man with clear cell renal cell carcinoma and suspected lung metastases, with a prior history of…
-
Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial
2 October 2026 · Nature Medicine
Nature Medicine published a randomized placebo-controlled trial examining how semaglutide may protect the kidneys in people with type 2 diabetes and chronic kidney disease. The study tested once-weekly subcutaneous semaglutide 1 mg against placebo over 52 weeks in 106 participants, including 25 women and 81 men. The…
-
Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial
2 October 2026 · Nature Medicine
Nature Medicine published a randomized placebo-controlled trial examining how semaglutide may protect the kidneys in people with type 2 diabetes and chronic kidney disease. The study tested once-weekly subcutaneous semaglutide 1 mg against placebo over 52 weeks in 106 participants, including 25 women and 81 men. The…
-
Fluorescent sensors could help researchers see diabetes in action
1 October 2026 · News-Medical
Researchers at the University of Bath have developed fluorescent molecular probes that can detect glucose changes inside living animals, offering a way to observe sugar uptake and metabolism in real time. The probes combine boronic acids, chemicals that selectively bind to sugars, with advanced imaging methods. In…
-
A wearable closed-loop insulin micropump toward a miniaturized artificial pancreas for diabetes
29 September 2026 · Microsystems & Nanoengineering
Researchers at the University of Electronic Science and Technology of China reported an open-access study describing a wearable, closed-loop insulin micropump intended as a step toward a smaller artificial pancreas. The device combines two functions that are often physically separated in current automated insulin…
-
Type 2 Diabetes Complications Rise Sharply Over Time
28 September 2026 · Knowridge Science Report
A large U.S. real-world study presented at the 2026 annual meeting of the European Association for the Study of Diabetes reports that people newly diagnosed with type 2 diabetes face a steep cumulative risk of chronic kidney disease, heart failure, or death over time. The findings come from the CALOR observational…
-
Stem-Like Immune Cells in Pancreatic Lymph Nodes May Help Explain Why Type 1 Diabetes
23 September 2026 · Medical Daily
Researchers at the University of Florida identified a population of stem-like immune cells in lymph nodes near the pancreas that may help sustain the autoimmune attack in type 1 diabetes. The study, published September 15 in the *Journal of Clinical Investigation*, used donated human pancreatic tissue and nearby lymph…
-
Marathons Safe For People With Type 1 Diabetes, Study Says
22 September 2026 · HealthDay
HealthDay reports on a small study suggesting that people with type 1 diabetes can safely complete a marathon and perform similarly to runners without diabetes when they use careful glucose, insulin, carbohydrate and hydration planning. The study involved 10 runners with type 1 diabetes and 10 runners without…
-
Bile Acids Show Surprising Spike in Early Diabetic Kidney Disease, Study Finds
21 September 2026 · Bioengineer.org
A study reported by Bioengineer.org describes new work from Tongji University School of Medicine in Shanghai suggesting that serum total bile acids may rise sharply during the earliest stage of diabetic kidney disease, then decline as the condition advances. The research, published in BMC Endocrine Disorders, focused…
-
Greater glycemic variability linked to improved next-day quality of life in diabetes
19 September 2026 · Healio
Healio reports on findings from the PRO-MENTAL study, which will be presented at the European Association for the Study of Diabetes annual meeting in Milan. The study followed 400 people with type 1 or type 2 diabetes for 14 days, combining self-reported quality-of-life measures with continuous glucose monitoring…